Yamo Pharmaceuticals Announces Autism Trial Registry Following Global Surge in Family Interest | Newswise
Newswise
Yamo Pharmaceuticals has established a global registry for families interested in its Phase 3 clinical trial for L1-79, an investigational drug targeting core symptoms of autism spectrum disorder (ASD), following a surge in inquiries from over 6,000 families in more than 90 countries. The registry aims to accelerate patient enrollment for the trial, which is expected to begin in early 2027, and is the only drug candidate advancing to Phase 3 specifically designed to treat ASD's core symptoms. Phase 2 results showed significant improvements in socialization and caregiver-reported outcomes with a favorable safety profile.
All articles from 9 October 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.